Workflow
鹭燕医药(002788.SZ)发布上半年业绩,归母净利润1.55亿元,下降18.83%

Core Viewpoint - Luyuan Pharmaceutical (002788.SZ) reported a decline in net profit for the first half of 2025, indicating potential challenges in maintaining profitability despite a slight increase in revenue [1] Financial Performance - The company's operating revenue reached 10.4 billion yuan, reflecting a year-on-year growth of 0.91% [1] - The net profit attributable to shareholders was 155 million yuan, representing a year-on-year decrease of 18.83% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 153 million yuan, down 17.93% year-on-year [1] - Basic earnings per share stood at 0.4 yuan [1]